Lantheus Holdings Contact | Compliance | Reimbursement | Supply Updates | Supplier Link
Investor Relations


Lantheus Holdings, Inc. is the parent company of Lantheus Medical Imaging, Inc. (“Lantheus”), which is a global leader in developing, manufacturing, selling and distributing innovative diagnostic image agents and products.

Our expertise in discovering, developing and commercializing innovative medical imaging agents provides a strong platform from which to bring forward breakthrough tools for the diagnosis and management of disease. Lantheus has a rich heritage and expertise in cardiovascular imaging and nuclear medicine, having pioneered many of the most significant products used in medical imaging.

Our current imaging agents primarily assist in the diagnosis of heart, vascular and other diseases using nuclear imaging, echocardiography and magnetic resonance imaging (MRI) technologies. We have a pipeline of next-generation and first-in-class products using Positron Emission Tomography (PET) and MRI technologies.

Our vision is to be the leading provider of innovative medical imaging solutions to improve human life. We are committed to developing next generation and first-in-class imaging agents to assist physicians in the diagnosis of heart, vascular and other diseases.

With direct operations in the United States, Puerto Rico, and Canada, we have a long and distinguished history of developing and commercializing innovative market-changing products.

Recent News

Lantheus Holdings Announces Divestiture of Its Australian Radiopharmacy Servicing Business and Entry into Long-Term Supply and Distribution Agreement

Transaction Simplifies Service and Distribution Model in Australia;

Expands International Reach of Products

NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Aug. 11, 2016-- Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), parent company of Lantheus Medical Imaging, Inc. (“LMI”), a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products, today announced the sale of its radiopharmacy servicing business in Australia to Global Medical Solutions, Ltd. (“GMS”). As part of the transaction, LMI and GMS also entered into a long-term supply and distribution contract under which LMI will continue to supply GMS and its affiliates with LMI’s products on commercial terms and under which GMS has agreed to certain product purchase commitments.

click here for the press release

Company Spotlight

Webcast Image

Q2 2016 Lantheus Holdings Earnings Conference Call
Thursday, August 4, 2016 at 4:30 p.m. ET


© 2015 Lantheus Medical Imaging, Inc. Contact | Compliance | Reimbursement | Supply Updates | Supplier Link | Site Map